Since 2014, when olaparib (AZD2281) was granted accelerated approval by the United States Food and Drug Administration (FDA) as monotherapy in inherited BRCA-mutated ovarian cancer,17,18 PARP inhibitors, including olaparib, rucaparib, niraparib, and talazoparib, have received approvals by FDA to be used in various cancers based on their revolutionary results in clinical trials (Fig. 1). Here, PARP1 is linked to ovarian carcinoma.